Fair point IMO. However Leerink seems to be doubting the platform.
"(AbbVie) needs something that is the cornerstone of the oncology franchise that they own and Rova-T was meant to be that," Porges said. "And now that cornerstone is cracked you wonder if they don't have to go out and find something else."
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.